[Ecstasy, new psychotropic drugs].
Djezzar
Samira
S
Centre d'évaluation et d'information sur la pharmacodépendance (CEIP)-addictovigilance, pôle addictologie-toxicologie-psychiatrie, Hôpital Fernand-Widal (AP-HP), Paris. samira.djezzar@lrb.aphp.fr
D019969:Amphetamine-Related Disorders / Q000453:epidemiology / Q000451:nursing* / Q000534:rehabilitation; D003430:Cross-Sectional Studies; D005602:France; D006213:Hallucinogens / Q000633:toxicity; D006801:Humans; D006885:Hydroxybutyrates / Q000633:toxicity; D013287:Illicit Drugs / Q000633:toxicity; D007649:Ketamine / Q000633:toxicity; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000633:toxicity; D010622:Phencyclidine / Q000633:toxicity
D006213:Hallucinogens; D006885:Hydroxybutyrates; D013287:Illicit Drugs; D007649:Ketamine; D010622:Phencyclidine; D018817:N-Methyl-3,4-methylenedioxyamphetamine